Citations

Clear

396 citation(s) found for "Spinner, M".

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
Pardanani, Animesh , Levine, Ross L. , Pikman, Yana , Wadleigh, Martha , Steensma, David P. , Elliott, Michelle A. , Wolanskyj, Alexandra P. , McClure, Rebecca F., Litzow, Mark R. , Gilliland, D. Gary , Tefferi, Ayalew , Lasho, Terra L. , Mesa, Ruben A. , Hogan, William J. , Wolanskyj-Spinner, Alexandra P , Steensma, David P

Mayo Clinic

Blood | July 25, 2006 | Volume: 108 | Issue: 10 | Pages: 3472-3476

10.1182/blood-2006-04-018879 | PMID 16868251 Get It

Abstract Recently, a gain-of-function MPL mutation, MPLW515L, was described in patients with JAK2V617F-negative myelofibrosis with myeloid metaplasia (MMM). To gain more information on mutational frequency, disease specificity, and clinical correlates, genomic DNA from 1182 patients with myeloproliferative and other myeloid disorders and 64 healthy controls was screened for MPL515 mutations, regardless of JAK2V617F mutational status: 290 with MMM, 242 with polycythemia vera, 318 with essential thrombocythemia (ET), 88 with myelodysplastic syndrome, 118 with chronic myelomonocytic leukemia, and 126 with acute myeloid leukemia (AML). MPL515 mutations, either MPLW515L (n = 17) or a previously undescribed MPLW515K (n = 5), were detected in 20 patients. The diagnosis of patients with mutant MPL alleles at the time of molecular testing was de novo MMM in 12 patients, ET in 4, post-ET MMM in 1, and MMM in blast crisis in 3. Six patients carried the MPLW515L and JAK2V617F alleles concurrently. We conclude that MPLW515L or MPLW515K mutations are present in patients with MMM or ET at a frequency of approximately 5% and 1%, respectively, but are not observed in patients with polycythemia vera (PV) or other myeloid disorders. Furthermore, MPL mutations may occur concurrently with the JAK2V617F mutation, suggesting that these alleles may have functional complementation in myeloproliferative disease.
The Cystic Transverse Limb of the Articular Branch: a Pathognomonic Sign Forperoneal Intraneural Ganglia Atthe Superior Tibiofibular Joint
Spinner, Robert J. , Desy, Nicholas M. , Amrami, Kimberly K.

Mayo Clinic

Neurosurgery | July 6, 2006 | Volume: 59 | Issue: 1 | Pages: 157-166

10.1227/01.neu.0000219820.31012.22 | PMID 16823312 Get It

Infraclavicular Ulnar Nerve Entrapment Due to a Chondroepitrochlearis Muscle
Spinner, Robert J. , Carmichael, S., Spinner, M

Mayo Clinic

Journal of Hand Surgery | June 17, 2005 | Volume: 16 | Issue: 3 | Pages: 315-317

10.1016/0266-7681(91)90060-2 | PMID 1960500 Get It

The chondroepitrochlearis muscle is an extremely rare muscle, arising from the pectoralis major, crossing over the neurovascular bundle in the axilla and inserting into the brachial fascia and medial epicondyle of the humerus. This paper presents the first known neurological complication due to the chondroepitrochlearis muscle.
Heterotopic Ossification of Peripheral Nerve (“Neuritis Ossificans”): Report of Two Cases
George, David H., Scheithauer, Bernd W., Spinner, Robert J. , Büchler, U, Cronin, Timothy E., Reedy, Michael T., Arndt, Byron C.

Mayo Clinic

Neurosurgery | July 30, 2004 | Volume: 51 | Issue: 1 | Pages: 244-246

10.1097/00006123-200207000-00039 | PMID 12182426 Get It

Abstract OBJECTIVE AND IMPORTANCE Heterotopic ossification (“neuritis ossificans”) is among the least frequently encountered reactive lesions in peripheral nerves. Only two cases have been described previously, one in the median nerve of a 34-year-old man, and the other in the ulnar nerve of an adult woman. The architecture of this lesion is distinctly zonal. Consisting of a central fibroblastic core, an intervening zone of osteoid production, and a peripheral layer of ossification, the pattern is remarkably similar to that of myositis ossificans. This similarity and the occurrence of the process in superficial nerves have led to speculation that trauma plays a role in its pathogenesis; this hypothesis remains unproved. We describe two additional cases of neuritis ossificans. CLINICAL PRESENTATION One patient, a 41-year-old man, experienced pain and numbness in the left leg for several months but had no history of local trauma. A mass was detected in the saphenous nerve. The second patient, a 16-year-old boy, noted subacute onset of pain in the popliteal fossa and decreased sensation in the distribution of the lateral sural cutaneous nerve. A mass was found within the tibial nerve at the knee level. INTERVENTION In each patient, resection of the mass required sacrifice of a segment of the nerve. CONCLUSION In each patient, the mass was composed of fibrovascular tissue with osteoid and bone deposition arranged in a zonal pattern. The ossifying process was intraneural but encased rather than directly involving nerve fascicles. These exceptionally intact examples of neuritis ossificans underscore its resemblance to myositis ossificans. Nerve-sparing resection of such masses is not always possible.
100 Years of Neurological Surgery at the Mayo Clinic
Spinner, Robert J. , Al-Rodhan, Nayef R. F. , Piepgras, David G.

Mayo Clinic

Neurosurgery | July 30, 2004 | Volume: 49 | Issue: 2 | Pages: 438-446

10.1097/00006123-200108000-00032 | PMID 11504121 Get It

Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia
Tefferi, Ayalew , Wolanskyj, Alexandra P. , Lasho, Terra L. , Mesa, Ruben A. , Wolanskyj-Spinner, Alexandra P

Mayo Clinic

Blood | January 5, 2004 | Volume: 103 | Issue: 9 | Pages: 3547-3548

10.1182/blood-2003-10-3505 | PMID 14701686 Get It

Abstract Recent studies have demonstrated neutrophil overexpression of the polycythemia rubra vera-1 (PRV-1) gene in polycythemia vera (PV) but not in secondary or spurious polycythemia (SP). To validate as well as expand upon this novel observation, we conducted a prospective study of 88 subjects: 30 with PV, 22 with SP, 14 with essential thrombocythemia (ET), 12 with myelofibrosis with myeloid metaplasia (MMM), and 10 controls. To minimize interstudy methodologic differences, we used a published real-time polymerase chain reaction (PCR)-based assay. The proportion of patients with increased neutrophil PRV-1 expression was 83% in PV, 21% in ET, 42% in MMM, 18% in SP, and 0% in controls. All 5 MMM patients with PRV-1 up-regulation had an antecedent history of PV. We conclude that neutrophil PRV-1 up-regulation is a characteristic feature of PV that may not be affected by fibrotic transformation. However, quantifying neutrophil PRV-1 mRNA, while complementary to other tests, is not in itself sufficient for the diagnosis of PV. (Blood. 2004;103:3547-3548)